Navigation Links
Patient Navigators Help Minority, Low-Income Cancer Patients Get Life-Saving Treatments
Date:10/30/2007

LOS ANGELES, Oct. 30 /PRNewswire/ -- Volunteers who guide low-income and minority cancer patients through cancer treatment, called lay patient navigators (LPN), help them to overcome major obstacles that prevent them from receiving quality care and achieving better outcomes, according to a study presented October 28, 2007, at the American Society for Therapeutic Radiology and Oncology's 49th Annual Meeting in Los Angeles.

Minority and low-income cancer patients continue to receive inferior care in the detection and treatment of cancer, compared to the general population. They are also under-represented in cancer clinical trials, which can potentially save or extend the lives of trial participants, especially those who have few treatment options.

To better understand how LPNs can help these at-risk patients, researchers studied nearly 500 African American and Latino cancer patients with mean family incomes below the poverty level. Almost two-thirds (60 percent) of patients studied accepted help from LPNs to overcome their barriers to getting cancer treatment. Results show that the time it took to reduce these barriers decreased from an average of 42 days to only one day. The study also showed that LPNs offered patients more access to participation in cancer clinical trials.

The study was conducted by the Urban Latino African American Cancer Disparities Project to identify and confront the root causes of treatment disparities in underserved communities and offer better access to clinical trials. It was supported by a grant from the National Cancer Institute's Cancer Disparity Research Program.

"Our study shows that LPNs can play an important role in reducing the healthcare disparities among minority and low-income patients by being their patient advocates," said David Khan, M.D., lead author of the study and a radiation oncologist at Centinela Freeman Medical Center in Inglewood, Calif. "These patient navigator programs should become an
'/>"/>

SOURCE American Society for Therapeutic Radiology and Oncology
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Monitoring Patient Glucose Levels: New Advances in software make it easier
2. Managing Preanalytical Processes for Patient Safety
3. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
4. Near-Patient Testing: The Advantages of C-Reactive Protein in Hematological Testing
5. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/686gwf/investigation ... Report on China,s Bevacizumab Market ,2010-2019" report to ... trade name of Avastin, bevacizumab injection is the first ... was approved by CFDA to treat metastatic colorectal cancer. ... all come from Roche and its subsidiary Genectech. ...
(Date:8/28/2015)... 2015 Research and ... of the "Investigation Report on China,s Quetiapine ... Developed by AstraZeneca plc, quetiapine (under the ... for the treatment of schizophrenia. Approved by CFDA ... in the Catalogue of Drugs for the Basic ...
(Date:8/28/2015)... Aug. 28, 2015  IP Shakti, LLC, today announced that ... Logo - http://photos.prnewswire.com/prnh/20150827/261551LOGO ... "Our new corporate identity signifies our transformation into a company ... analytics platform for patent claim validity." ... the proprietary AIA Shield™ platform, the Company commenced a corporate ...
Breaking Medicine Technology:Investigation Report on China's Bevacizumab Market 2015-2019 2China Quetiapine Market Investigation Report 2010-2019 2IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2
... Tenn., Aug. 30 ,Palatin Technologies, Inc. (Amex: ... ) announced today that they have delayed plans ... bremelanotide, a first in class,melanocortin agonist drug candidate, ... decision follows responses from representatives of,the U.S. Food ...
... FRANCISCO, Calif., Aug. 29 ,Exelixis, Inc. (Nasdaq: EXEL ... for analysts and investors in conjunction with the International,Association ... Conference on,Lung Cancer. The webcast will be held on ... During the webcast, Exelixis management will,discuss data from a ...
Cached Medicine Technology:King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction 2Exelixis Announces September 5 Webcast of Its 2007 IASLC Investor and Analyst Briefing 2
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... For Dallas, ... is taking part with their subsidiary USPI Tenet Health. , The American Heart Association ... heart disease and stroke. They believe that together, a difference can be made. Walkers ...
(Date:8/28/2015)... ... ... The 6th Annual Survivor in the City, Chicago silent auction and cocktail ... its cadre of widespread support—an official letter of support and gratitude from the Mayor ... and the University of Illinois at Chicago’s Department of Neurosurgery, the Brain Aneurysm Foundation ...
(Date:8/28/2015)... ... ... Saint Petersburg, FL —Pocket Protein™, a protein beverage that ... lactose or caffeine in a convenient 2 oz. pouch that never needs refrigeration, ... , Five consumer packaged goods (CPG) products were selected by the SupplySide editorial ...
(Date:8/28/2015)... Boynton Beach, FL. (PRWEB) , ... August 28, ... ... creating problems for businesses nationwide. Addictions specialist, Dr. James Strawbridge, gives a new ... Strawbridge believes that it should begin with the employer and employees getting together ...
(Date:8/28/2015)... ... 28, 2015 , ... CARF International announced that West Ridge ... treatment and intensive family based services. , By pursuing and achieving accreditation, West ... of excellence. As a nonprofit charity for more than 50 years, West Ridge ...
Breaking Medicine News(10 mins):Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 3Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3Health News:West Ridge Academy Awarded CARF Three-Year Accrediation 2
... Cellular damage induced by oxygen free radicals may be ... new study. //This groundbreaking study conducted by neuroscientists at ... of complex I, a protein that plays a major ... has been blamed for cellular damage in Parkinson’s disease. ...
... yet ascertained the top floors of the Melbourne office block ... the cause of illnesses.// ,Tests on radiofrequency emissions, ... any link as yet to the seven cases of brain ... of these seven cases were employees who had worked on ...
... genetic disorder which completely affects the immune system. In ... //therapy was successfully used to cure this life threatening ... Of Veterinary Medicine and the National Institute of Allergy ... as a vector for the correct gene of XSCID. ...
... of several previous studies of TNF- (tumor necrosis factor) ... that use of these drugs causes an increased risk ... study shows a strong association between treatment with TNF-blocking ... pneumonia, and cancers,' says Eric Matteson, M.D., Mayo Clinic ...
... a pigment that imparts tomatoes its characteristic red color ... ideal for prevention of strokes and heart attacks.// Previous ... chemical. ,According to scientists, the stickiness of ... - was reduced by 70 percent when 220 volunteers ...
... issue of Cancer Cell says that scientists have identified ... how cancer progresses.// This molecule was found to inhibit ... vivo as well as in vitro. , ,This ... inhibitors must display a broad reactivity to effectively attenuate ...
Cached Medicine News:Health News:Oxygen-Induced Damage A Leading Cause For Parkinson’s Diseas 2Health News:In-Vivo Gene Therapy Technique to Cure XSCID in Basset Pups 2Health News:In-Vivo Gene Therapy Technique to Cure XSCID in Basset Pups 3Health News:Risk of Cancer from Drugs for Rheumatoid Arthritis 2Health News:Risk of Cancer from Drugs for Rheumatoid Arthritis 3Health News:Discovery Of New Molecule Could Solve Cancer Spread Mystery 2
... point-of-care device for the qualitative detection of drug ... TOX/See device can detect up to nine of ... 8 minutes and requires only a few drops ... to maximize convenience and ease of use. TOX/See ...
... point-of-care device for the qualitative detection of drug ... TOX/See device can detect up to nine of ... 8 minutes and requires only a few drops ... to maximize convenience and ease of use. TOX/See ...
... hand-held, point-of-care device for the qualitative detection of ... The TOX/See device can detect up to nine ... to 8 minutes and requires only a few ... packaged to maximize convenience and ease of use. ...
... is a 1-step, hand-held, point-of-care device for the ... human urine. The TOX/See device can detect ... drugs in 3 to 8 minutes and requires ... cassette is individually packaged to maximize convenience and ...
Medicine Products: